Mounjaro for Hair loss

tirzepatide · Investigational / off-label

Last updated 2026-05-28 15:46 UTC

Mounjaro (tirzepatide) is not FDA-approved for hair loss. Two studies suggest a possible association between tirzepatide and hair loss, but these findings do not establish causation or approval for this use.

AI summary of the sources below.

Drug	Mounjaro (tirzepatide)
Condition	Hair loss
Approval status	Investigational / off-label
Research papers	2

Mounjaro is not FDA-approved for hair loss; the research below reflects investigational or off-label study only.

Research on tirzepatide for hair loss (2)

Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol · 2025 · 27 citations
Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. J Am Acad Dermatol · 2026 · 0 citations

Search PubMed ↗